DOCSLIB.ORG

Characterization of Novel Pharmacological Caspase-6 Inhibitors Provides Insight on Developing Treatments Against Alzheimer Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Characterization of Novel Pharmacological Caspase-6 Inhibitors Provides Insight on Developing Treatments Against Alzheimer Disease Characterization of novel pharmacological Caspase-6 inhibitors provides insight on developing treatments against Alzheimer disease by Prateep Pakavathkumar Department of the Integrated Program in Neuroscience, McGill University, Montreal June 2017 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Prateep Pakavathkumar, 2017 "If I have seen further than others, it is by standing upon the shoulders of Giants” - Sir Isaac Newton Table of contents Table of contents ..................................................................................................... i Abstract ................................................................................................................ vii Résumé ............................................................................................................... viii Preface .................................................................................................................... x First-authored manuscripts ................................................................................................. x Author contributions ........................................................................................................... xi Collaborative manuscripts ................................................................................................. xii Acknowledgements ............................................................................................ xiii Abbreviations list ................................................................................................ xiv List of Tables ....................................................................................................... xix List of Figures ...................................................................................................... xx Introduction ............................................................................................................ 1 1. Literature Review ............................................................................................... 4 1.1 Apoptosis .......................................................................................................................... 4 1.1.1 The discovery of apoptosis ........................................................................................ 4 1.2 Discovering caspases and link to cell death proteases ................................................. 4 1.2.1 The evolution of caspases .......................................................................................... 4 1.2.2 The first mammalian caspase ..................................................................................... 5 1.2.3 Apoptosis in Caenorhabditis elegans ......................................................................... 5 1.2.4 The mammalian caspases ........................................................................................... 6 1.3 Caspases are classified based on sequence similarities, substrate preferences, or function ................................................................................................................................ 13 1.3.1 Phylogenetic classification of human caspases ........................................................ 14 1.3.2 Substrate preference-based classification of human caspases ................................. 14 1.3.3 Functional classification of human caspases ........................................................... 15 1.4 Molecular platforms for apoptotic and inflammatory pathways ............................. 16 1.4.1 The death-inducing signaling complex and the extrinsic pathway .......................... 17 1.4.2 The apoptosome and the intrinsic apoptotic pathway .............................................. 19 1.4.3 The inflammasomes and pyroptosis......................................................................... 20 1.4.4 The PIDDosome and mitotic catastrophe ................................................................ 21 1.4.5 The Ripoptosome at the crossroads between apoptosis and necroptosis ................. 22 1.5 Caspase functions in apoptosis and beyond................................................................ 22 1.5.1 Caspase functions in systematic dismantling of dying cells .................................... 23 1.5.2 Non-apoptotic caspase functions in immune cells ................................................... 24 1.5.3 Non-apoptotic caspase functions in the nervous system.......................................... 25 1.5.4 Other non-apoptotic functions ................................................................................. 27 1.6 Caspase-6 transcriptional control, alternative splicing, and tissue expression ....... 29 1.6.1 Little is known about CASP6 gene transcriptional regulation ................................. 29 1.6.2 The alternatively spliced Caspase-6 isoform ........................................................... 31 1.6.3 Caspase-6 is expressed at low levels in the healthy brain ....................................... 32 1.7 Caspase-6 enzyme structural analysis ......................................................................... 33 1.7.1 The 3D structure of Caspase-6 and its active site .................................................... 33 1.7.2 Unprocessed inactive Caspase-6 .............................................................................. 34 1.7.3 Caspase-6 processing by inter- and intramolecular cleavage .................................. 34 1.7.4 Changes in the Caspase-6 active site upon substrate binding and pH ..................... 35 1.8 Caspase-6 post-translation modifications (PTMs) ..................................................... 36 1.8.1 Caspase-6 phosphorylation at serine 257 ................................................................. 37 1.8.2 Caspase-6 palmitoylation at cysteine residues ......................................................... 37 1.9 Caspase-6 activation follows canonical activation cascades and can self-activate .. 38 1.9.1 Caspase-6 is activated both downstream and upstream of other caspases ............... 39 1.9.2 Caspase-6 self-activates in mammalian cells ........................................................... 40 1.10 Caspase-6 substrates and protein interaction analysis ............................................ 40 1.10.1 Caspase-6 cleaves many cytoskeletal proteins in human neurons ......................... 40 1.10.2 Caspase-6 signalling pathways in human T lymphocytes ..................................... 41 1.10.3 Caspase-6 protein-protein interaction network ...................................................... 42 ii 1.11 Caspase-6 mediates axonal degeneration.................................................................. 43 1.11.1 Caspase-6 is activated in peripheral neurons leading to axonal degeneration ....... 44 1.11.2 Caspase-6-mediated axonal degeneration in the CNS ........................................... 45 1.12 Caspase-6 is activated early in Alzheimer disease ................................................... 47 1.12.1 Caspase-6 is activated in sporadic and familial AD brains.................................... 48 1.12.2 Caspase-6 is activated early during AD pathogenesis ........................................... 48 1.12.3 Caspase-6 activity can increase A production, disrupt the cytoskeleton, and impair the ubiquitin-proteasome system ...................................................................................... 49 1.12.4 Caspase-6 is part of a pro-inflammatory cycle in AD brains ................................. 50 1.13 Caspase-6 activation in other neurodegenerative diseases...................................... 51 1.13.1 Caspase-6 cleaves mutant huntingtin protein in mouse models ............................ 51 1.13.2 Caspase-6 cleaves DJ-1 in PD ............................................................................... 52 1.13.3 Caspase-6 is activated following ischemic stroke ................................................. 53 1.14 Caspase-6 inhibitors: proteins, peptides, and small molecules ............................... 55 1.14.1 Endogenous protein Caspase-6 inhibitors .............................................................. 56 1.14.2 Zinc-mediated Caspase-6 inhibition ...................................................................... 58 1.14.3 Pharmacological Caspase-6 inhibitors ................................................................... 58 1.15 Hypothesis and Thesis objectives .............................................................................. 61 1.16 Figures and legends..................................................................................................... 62 1.17 Tables ........................................................................................................................... 72 2. Methylene blue inhibits caspases by oxidation of the catalytic cysteine ......... 77 2.1 Preface ............................................................................................................................ 77 2.2 Abstract .......................................................................................................................... 77 2.3 Introduction ................................................................................................................... 78 2.4 Results ............................................................................................................................ 80
Load more

Recommended publications
  • Manner Via Caspase-8 in an RIP3
    Cutting Edge: FAS (CD95) Mediates Noncanonical IL-1 β and IL-18 Maturation via Caspase-8 in an RIP3-Independent Manner This information is current as of October 2, 2021. Lukas Bossaller, Ping-I Chiang, Christian Schmidt-Lauber, Sandhya Ganesan, William J. Kaiser, Vijay A. K. Rathinam, Edward S. Mocarski, Deepa Subramanian, Douglas R. Green, Neal Silverman, Katherine A. Fitzgerald, Ann Marshak-Rothstein and Eicke Latz Downloaded from J Immunol 2012; 189:5508-5512; Prepublished online 9 November 2012; doi: 10.4049/jimmunol.1202121 http://www.jimmunol.org/content/189/12/5508 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2012/11/12/jimmunol.120212 Material 1.DC1 References This article cites 30 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/189/12/5508.full#ref-list-1 by guest on October 2, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved.
    [Show full text]
  • The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies
    Hindawi Publishing Corporation International Journal of Cell Biology Volume 2010, Article ID 215158, 21 pages doi:10.1155/2010/215158 Review Article TheRoleofCyclooxygenase-2inCellProliferationandCell Death in Human Malignancies Cyril Sobolewski,1 Claudia Cerella,1 Mario Dicato,1 Lina Ghibelli,2 and Marc Diederich1 1 LaboratoiredeBiologieMol´eculaire et Cellulaire du Cancer, Hopitalˆ Kirchberg, 9 rue Edward Steichen, 2540 Luxembourg, Luxembourg 2 Dipartimento di Biologia, Universita` di Roma di Roma Tor Vergata, Via Ricerca Scientifica snc, 00133 Rome, Italy Correspondence should be addressed to Marc Diederich, [email protected] Received 16 July 2009; Accepted 18 December 2009 Academic Editor: Simone Fulda Copyright © 2010 Cyril Sobolewski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. It is well admitted that the link between chronic inflammation and cancer involves cytokines and mediators of inflammatory pathways, which act during the different steps of tumorigenesis. The cyclooxygenases (COXs) are a family of enzymes, which catalyze the rate-limiting step of prostaglandin biosynthesis. This family contains three members: ubiquitously expressed COX- 1, which is involved in homeostasis; the inducible COX-2 isoform, which is upregulated during both inflammation and cancer; and COX-3, expressed in brain and spinal cord, whose functions remain to be elucidated. COX-2 was described to modulate cell proliferation and apoptosis mainly in solid tumors, that is, colorectal, breast, and prostate cancers, and, more recently, in hematological malignancies. These findings prompt us to analyze here the effects of a combination of COX-2 inhibitors together with different clinically used therapeutic strategies in order to further improve the efficiency of future anticancer treatments.
    [Show full text]
  • Biochemical Society Focused Meetings Proteases A
    ORE Open Research Exeter TITLE Proteases and caspase-like activity in the yeast Saccharomyces cerevisiae. AUTHORS Wilkinson, D; Ramsdale, M JOURNAL Biochemical Society Transactions DEPOSITED IN ORE 18 November 2013 This version available at http://hdl.handle.net/10871/13957 COPYRIGHT AND REUSE Open Research Exeter makes this work available in accordance with publisher policies. A NOTE ON VERSIONS The version presented here may differ from the published version. If citing, you are advised to consult the published version for pagination, volume/issue and date of publication Biochemical Society Transactions (2011) XX, (XX-XX) (Printed in Great Britain) Biochemical Society Focused Meetings Proteases and caspase-like activity in the yeast Saccharomyces cerevisiae Derek Wilkinson and Mark Ramsdale1 Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, EX4 4QD Key words: Programmed cell death, apoptosis, necrosis, proteases, caspases, Saccharomyces cerevisiae. Abbreviations used: PCD, programmed cell death; ROS, reactive oxygen species; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ER, endoplasmic reticulum; MS, mass spectrometry. 1email [email protected] Abstract A variety of proteases have been implicated in yeast PCD including the metacaspase, Mca1 and the separase Esp1, the HtrA-like serine protease Nma111, the cathepsin-like serine carboxypeptideases and a range of vacuolar proteases. Proteasomal activity is also shown to have an important role in determining cell fate, with both pro- and anti-apoptotic roles. Caspase-3, -6- and -8 like activities are detected upon stimulation of yeast PCD, but not all of this activity is associated with Mca1, implicating other proteases with caspase-like activity in the yeast cell death response.
    [Show full text]
  • Apoptotic Threshold Is Lowered by P53 Transactivation of Caspase-6
    Apoptotic threshold is lowered by p53 transactivation of caspase-6 Timothy K. MacLachlan*† and Wafik S. El-Deiry*‡§¶ʈ** *Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, and Departments of ‡Medicine, §Genetics, ¶Pharmacology, and ࿣Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Communicated by Britton Chance, University of Pennsylvania School of Medicine, Philadelphia, PA, April 23, 2002 (received for review January 11, 2002) Little is known about how a cell’s apoptotic threshold is controlled Inhibition of the enzyme reduces the sensitivity conferred by after exposure to chemotherapy, although the p53 tumor suppres- overexpression of p53. These results identify a pathway by which sor has been implicated. We identified executioner caspase-6 as a p53 is able to accelerate the apoptosis cascade by loading the cell transcriptional target of p53. The mechanism involves DNA binding with cell death proteases so that when an apoptotic signal is by p53 to the third intron of the caspase-6 gene and transactiva- received, programmed cell death occurs rapidly. tion. A p53-dependent increase in procaspase-6 protein level al- lows for an increase in caspase-6 activity and caspase-6-specific Materials and Methods Lamin A cleavage in response to Adriamycin exposure. Specific Western Blotting and Antibodies. Immunoblotting was carried out by inhibition of caspase-6 blocks cell death in a manner that correlates using mouse anti-human p53 monoclonal (PAb1801; Oncogene), with caspase-6 mRNA induction by p53 and enhances long-term rabbit anti-human caspase-3 (Cell Signaling, Beverly, MA), mouse survival in response to a p53-mediated apoptotic signal.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • The Role of Caspase-2 in Regulating Cell Fate
    cells Review The Role of Caspase-2 in Regulating Cell Fate Vasanthy Vigneswara and Zubair Ahmed * Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK; [email protected] * Correspondence: [email protected] Received: 15 April 2020; Accepted: 12 May 2020; Published: 19 May 2020 Abstract: Caspase-2 is the most evolutionarily conserved member of the mammalian caspase family and has been implicated in both apoptotic and non-apoptotic signaling pathways, including tumor suppression, cell cycle regulation, and DNA repair. A myriad of signaling molecules is associated with the tight regulation of caspase-2 to mediate multiple cellular processes far beyond apoptotic cell death. This review provides a comprehensive overview of the literature pertaining to possible sophisticated molecular mechanisms underlying the multifaceted process of caspase-2 activation and to highlight its interplay between factors that promote or suppress apoptosis in a complicated regulatory network that determines the fate of a cell from its birth and throughout its life. Keywords: caspase-2; procaspase; apoptosis; splice variants; activation; intrinsic; extrinsic; neurons 1. Introduction Apoptosis, or programmed cell death (PCD), plays a pivotal role during embryonic development through to adulthood in multi-cellular organisms to eliminate excessive and potentially compromised cells under physiological conditions to maintain cellular homeostasis [1]. However, dysregulation of the apoptotic signaling pathway is implicated in a variety of pathological conditions. For example, excessive apoptosis can lead to neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, whilst insufficient apoptosis results in cancer and autoimmune disorders [2,3]. Apoptosis is mediated by two well-known classical signaling pathways, namely the extrinsic or death receptor-dependent pathway and the intrinsic or mitochondria-dependent pathway.
    [Show full text]
  • Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L
    University of Massachusetts Amherst ScholarWorks@UMass Amherst Open Access Dissertations 5-2012 Regulation of Caspase-9 by Natural and Synthetic Inhibitors Kristen L. Huber University of Massachusetts Amherst, [email protected] Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations Part of the Chemistry Commons Recommended Citation Huber, Kristen L., "Regulation of Caspase-9 by Natural and Synthetic Inhibitors" (2012). Open Access Dissertations. 554. https://doi.org/10.7275/jr9n-gz79 https://scholarworks.umass.edu/open_access_dissertations/554 This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Submitted to the Graduate School of the University of Massachusetts Amherst in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY MAY 2012 Chemistry © Copyright by Kristen L. Huber 2012 All Rights Reserved REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS A Dissertation Presented by KRISTEN L. HUBER Approved as to style and content by: _________________________________________ Jeanne A. Hardy, Chair _________________________________________ Lila M. Gierasch, Member _________________________________________ Robert M. Weis,
    [Show full text]
  • Caspase-6 Induces 7A6 Antigen Localization to Mitochondria During FAS-Induced Apoptosis of Jurkat Cells HIROAKI SUITA, TAKAHISA SHINOMIYA and YUKITOSHI NAGAHARA
    ANTICANCER RESEARCH 37 : 1697-1704 (2017) doi:10.21873/anticanres.11501 Caspase-6 Induces 7A6 Antigen Localization to Mitochondria During FAS-induced Apoptosis of Jurkat Cells HIROAKI SUITA, TAKAHISA SHINOMIYA and YUKITOSHI NAGAHARA Division of Life Science and Engineering, School of Science and Engineering, Tokyo Denki University, Hatoyama, Japan Abstract. Background: Mitochondria are central to caspases (caspase-8 and -9) that activate effector caspases (1). apoptosis. However, apoptosis progression involving Caspases are constructed of a pro-domain, a large subunit, and mitochondria is not fully understood. A factor involved in a small subunit. Upon caspase activation, cleavage of the mitochondria-mediated apoptosis is 7A6 antigen. 7A6 caspase occurs. Caspase-6 and -7, which are effector caspases, localizes to mitochondria from the cytosol during apoptosis, each have a large subunit that is 20 kDa (p20) and a small which seems to involve ‘effector’ caspases. In this study, we subunit that is 10 kDa (p10), but caspase-3, which is also an investigated the precise role of effector caspases in 7A6 effector caspase, has a large subunit of 17 kDa and a small localization to mitochondria during apoptosis. Materials and subunit of 12 kDa (p12) (2-4). Moreover, the large and small Methods: Human T-cell lymphoma Jurkat cells were treated subunits of caspase-6 and -7 are connected by a linker, but with an antibody against FAS. 7A6 localization was analyzed caspase-3 does not have a linker (Figure 1). The difference by confocal laser scanning microscopy and flow cytometry. between effector and initiator caspases is that the pro-domain Caspases activation was determined by western blot of an initiator caspase is long and that the pro-domain of an analysis.
    [Show full text]
  • Constitutive Activation of Caspase-3 and Poly ADP Ribose Polymerase Cleavage in Fanconi Anemia Cells
    Published OnlineFirst January 12, 2010; DOI: 10.1158/1541-7786.MCR-09-0373 Molecular DNA Damage and Cellular Stress Responses Cancer Research Constitutive Activation of Caspase-3 and Poly ADP Ribose Polymerase Cleavage in Fanconi Anemia Cells Alex Lyakhovich1,2 and Jordi Surrallés1,3 Abstract Fanconi anemia (FA) is a rare syndrome characterized by developmental abnormalities, progressive bone mar- row failure, and cancer predisposition. Cells from FA patients exhibit hypersensitivity to DNA cross-linking agents and oxidative stress that may trigger apoptosis. Damage-induced activation of caspases and poly ADP ribose polymerase (PARP) enzymes have been described for some of the FA complementation groups. Here, we show the constitutive activation of caspase-3 and PARP cleavage in the FA cells without exposure to exogenous DNA-damaging factors. These effects can be reversed in the presence of reactive oxygen species scavenger N- acetylcystein. We also show the accumulation of oxidized proteins in FA cells, which is accompanied by the tumor necrosis factor (TNF)-α oversecretion and the upregulation of early stress response kinases pERK1/2 and p-P38. Suppression of TNF-α secretion by the extracellular signal-regulated kinase inhibitor PD98059 results in reduction of caspase-3 cleavage, suggesting a possible mechanism of caspases-3 activation in FA cells. Thus, the current study is the first evidence demonstrating the damage-independent activation of caspase-3 and PARP in FA cells, which seems to occur through mitogen-activated protein kinase activation and TNF-α oversecretion. Mol Cancer Res; 8(1); 46–56. ©2010 AACR. Introduction Cells derived from FA patients are hypersensitive to cross- linking agents that are potent inducers of programmed cell Fanconi anemia (FA) is a genetic disorder characterized death (PCD or apoptosis; ref.
    [Show full text]
  • Caspase Substrates and Inhibitors
    Downloaded from http://cshperspectives.cshlp.org/ on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press Caspase Substrates and Inhibitors Marcin Pore˛ba1, Aleksandra Stro´z˙yk1, Guy S. Salvesen2, and Marcin Dra˛g1 1Department of Bioorganic Chemistry, Faculty of Chemistry, Wroclaw University of Technology, 50-370 Wrocław, Poland 2Program in Cell Death Research, Sanford-Burnham Medical Research Institute, La Jolla, California 92024 Correspondence: [email protected] Caspases are proteases at the heart of networks that govern apoptosis and inflammation. The past decade has seen huge leaps in understanding the biology and chemistry of the caspases, largely through the development of synthetic substrates and inhibitors. Such agents are used to define the role of caspases in transmitting life and death signals, in imaging caspases in situ and in vivo, and in deconvoluting the networks that govern cell behavior. Additionally, focused proteomics methods have begun to reveal the natural substrates of caspases in the thousands. Together, these chemical and proteomics technologies are setting the scene for designing and implementing control of caspase activity as appropriate targets for disease therapy. WHAT IT TAKES TO BE A CASPASE group, known as cysteine protease clan CD that he need to recycle scarce amino acids in early also contains the plant metacaspases (Vercam- Tbiotic environments required that proteases men et al. 2004), and mammalian and plant were among the first proteins to appear in the proteases of the legumain family (involved in most primitive replicating organisms. Since that specific processing events), the eukaryotic pro- distant origin, proteases have diversified into tease separase (required for sisterchromatid sep- every biological niche, occupied every cellular aration during mitosis), and the bacterial prote- and extracellular compartment, and are encod- ases clostripain and gingipain (Chen et al.
    [Show full text]
  • Executioner Caspase-3 and Caspase-7 Are Functionally Distinct Proteases
    Executioner caspase-3 and caspase-7 are functionally distinct proteases John G. Walsh, Sean P. Cullen, Clare Sheridan, Alexander U. Luthi,¨ Christopher Gerner*, and Seamus J. Martin† Molecular Cell Biology Laboratory, Department of Genetics, The Smurfit Institute, Trinity College, Dublin 2, Ireland Edited by Doug R. Green, St. Jude Children’s Research Hospital, Memphis, TN, and accepted by the Editorial Board July 8, 2008 (received for review August 15, 2007) Members of the caspase family of cysteine proteases play central CASP-3 and CASP-7 on the B6 background die immediately roles in coordinating the stereotypical events that occur during after birth because of defective heart development (9). The latter apoptosis. Because the major executioner caspases, caspase-3 and result suggests that there may be a degree of functional com- caspase-7, exhibit almost indistinguishable activity toward certain pensation in operation between caspase-3 and caspase-7, synthetic peptide substrates, this has led to the widespread view whereas the knockout phenotypes observed on the 129 back- that these proteases occupy functionally redundant roles within ground suggest that caspase-3 and caspase-7 serve distinct roles. the cell death machinery. However, the distinct phenotypes of mice However, a major problem in interpreting these data is that the deficient in either of these caspases, as well as mice deficient in relative expression levels of caspase-3 and caspase-7 may vary both, is at odds with this view. These distinct phenotypes could be dramatically between mouse strains, as well as within particular related to differences in the relative expression levels of caspase-3 tissues.
    [Show full text]
  • Cells and Human Dermal Microvessel Endothelial Cells: the Role of JNK1
    The Journal of Immunology Lipopolysaccharide-Induced Apoptosis in Transformed Bovine Brain Endothelial Cells and Human Dermal Microvessel Endothelial Cells: The Role of JNK1 Hisae Karahashi,*† Kathrin S. Michelsen,*‡ and Moshe Arditi2* Stimulation of transformed bovine brain endothelial cells (TBBEC) with LPS leads to apoptosis while human microvessel endo- thelial cells (HMEC) need the presence of cycloheximide (CHX) with LPS to induce apoptosis. To investigate the molecular mechanism of LPS-induced apoptosis in HMEC or TBBEC, we analyzed the involvement of MAPK and PI3K in TBBEC and HMEC. LPS-induced apoptosis in TBBEC was hallmarked by the activation of caspase 3, caspase 6, and caspase 8 after the stimulation of LPS, followed by poly(ADP-ribose) polymerase cleavage and lactate dehydrogenase release. We also observed DNA cleavage determined by TUNEL staining in TBBEC treated with LPS. Herbimycin A, a tyrosine kinase inhibitor, and SP600125, a JNK inhibitor, suppressed the activation of caspases and lactate dehydrogenase release. Moreover, a PI3K inhibitor (LY294002) suppressed activation of caspases and combined treatment with both SP600125 and LY294002 completely inhibited the activation of caspases. These results suggest that the JNK signaling pathway through the tyrosine kinase and PI3K pathways is involved in the induction of apoptosis in LPS-treated TBBEC. On the other hand, we observed sustained JNK activation in HMEC treated with LPS and CHX, and neither ERK1/2 nor AKT were activated. The addition of SP600125 suppressed phosphorylation of JNK and the activation of caspase 3 in HMEC treated with LPS and CHX. These results suggest that JNK plays an important role in the induction of apoptosis in endothelial cells.
    [Show full text]